HCSGD entry for RUNX1T1
1. General information
| Official gene symbol | RUNX1T1 |
|---|---|
| Entrez ID | 862 |
| Gene full name | runt-related transcription factor 1; translocated to, 1 (cyclin D-related) |
| Other gene symbols | AML1T1 CBFA2T1 CDR ETO MTG8 ZMYND2 |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
This gene isn't in Literature mining network.
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0003677 | DNA binding | IEA | molecular_function |
| GO:0003700 | Sequence-specific DNA binding transcription factor activity | IEA | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005634 | Nucleus | IEA | cellular_component |
| GO:0006091 | Generation of precursor metabolites and energy | TAS | biological_process |
| GO:0006351 | Transcription, DNA-templated | IEA | biological_process |
| GO:0006355 | Regulation of transcription, DNA-templated | IEA | biological_process |
| GO:0016363 | Nuclear matrix | IDA | cellular_component |
| GO:0042802 | Identical protein binding | IPI | molecular_function |
| GO:0042803 | Protein homodimerization activity | IEA | molecular_function |
| GO:0045444 | Fat cell differentiation | IEA | biological_process |
| GO:0046872 | Metal ion binding | IEA | molecular_function |
| GO:0051101 | Regulation of DNA binding | IEA | biological_process |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.7850455036 | 0.0020280802 | 0.9999902473 | 0.0859176000 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | Down | -0.0193831106 |
| GSE13712_SHEAR | Down | -2.1831614065 |
| GSE13712_STATIC | Down | -1.5476383119 |
| GSE19018 | Down | -0.4935235462 |
| GSE19899_A1 | Down | -0.1251371323 |
| GSE19899_A2 | Down | -1.2812933165 |
| PubMed_21979375_A1 | Down | -0.2195948075 |
| PubMed_21979375_A2 | Down | -0.8835229959 |
| GSE35957 | Up | 0.3284693076 |
| GSE36640 | Down | -0.7196750069 |
| GSE54402 | Down | -0.6385500932 |
| GSE9593 | Up | 0.3041146143 |
| GSE43922 | Down | -0.4412777766 |
| GSE24585 | Down | -1.3100011406 |
| GSE37065 | Down | -0.3826347491 |
| GSE28863_A1 | Up | 1.2180467892 |
| GSE28863_A2 | Up | 0.5656104600 |
| GSE28863_A3 | Down | -0.1162905339 |
| GSE28863_A4 | Down | -0.0355335951 |
| GSE48662 | Down | -0.0103617330 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Not regulated by compounds
- Drugs
Not regulated by drugs
- MicroRNAs
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-miR-106b-5p | MIMAT0000680 | MIRT020443 | Microarray | Functional MTI (Weak) | 17242205 |
| hsa-miR-103a-3p | MIMAT0000101 | MIRT027124 | Sequencing | Functional MTI (Weak) | 20371350 |
| hsa-miR-16-5p | MIMAT0000069 | MIRT031791 | Sequencing | Functional MTI (Weak) | 20371350 |
| hsa-let-7e-5p | MIMAT0000066 | MIRT051459 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
No target information from mirRecord
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 3 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 26690546 | The antitumor drug etoposide (ETO) is widely used in treating several cancers, including adrenocortical tumor (ACT) |
| 26690546 | Here, we checked the effect of sublethal dose of ETO in ACT cells |
| 26690546 | Sublethal dose of ETO treatment did not induce cell death but arrested the ACT cells in G2/M phase |
| 26690546 | In addition, autophagy was activated by ETO and was required for ACT cell survival |
| 26690546 | Chloroquine alleviated CDK2 and ERK, but not Chk2, activation and thus inhibited centrosome amplification in either ETO- or hydroxyurea-treated ACT cells |
| 26690546 | In addition, chloroquine also inhibited centrosome amplification in osteosarcoma U2OS cell lines when treated with ETO or hydroxyurea |
| 26102294 | Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively) |
| 26102294 | PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe |
| 26102294 | SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function |
| 12091906 | The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia |
| 12091906 | This translocation creates a fusion protein consisting of the acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor (AML1 ETO), which represses transcription through AML1 (RUNX1) DNA binding sites and immortalizes hematopoietic progenitor cells |
| 12091906 | We have identified the p14(ARF) tumor suppressor, a mediator of the p53 oncogene checkpoint, as a direct transcriptional target of AML1 ETO |
| 12091906 | AML1 ETO repressed the p14(ARF) promoter and reduced endogenous levels of p14(ARF) expression in multiple cell types |
| 12091906 | Chromatin immunoprecipitation assays demonstrated that AML1 ETO was specifically bound to the p14(ARF) promoter |
Entries Per Page
Displaying Page of
